SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bernhard K. Krämer, Giuseppe Montagnino, Bernd Krüger, Raimund Margreiter, Christoph J. Olbricht, Roberto Marcen, Urban Sester, Ulrich Kunzendorf, Karl-Heinz Dietl, Paolo Rigotti, Claudio Ronco, Silke Hörsch, Bernhard Banas, Ferdinand Mühlbacher, Manuel Arias, Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results, Transplant International, 2016, 29, 3
  2. 2
    G. Muduma, W. M. Hart, S. Patel, A. O. Odeyemi, Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients, Current Medical Research and Opinion, 2016, 1

    CrossRef

  3. 3
    Emily Brooks, Susan E. Tett, Nicole M. Isbel, Christine E. Staatz, Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?, Clinical Pharmacokinetics, 2016,

    CrossRef

  4. 4
    Jeffery M. Venner, Konrad S. Famulski, Jeff Reeve, Jessica Chang, Philip F. Halloran, Relationships among injury, fibrosis, and time in human kidney transplants, JCI Insight, 2016, 1, 1

    CrossRef

  5. 5
    Stephen T. Bartlett, James F. Markmann, Paul Johnson, Olle Korsgren, Bernhard J. Hering, David Scharp, Thomas W. H. Kay, Jonathan Bromberg, Jon S. Odorico, Gordon C. Weir, Nancy Bridges, Raja Kandaswamy, Peter Stock, Peter Friend, Mitsukazu Gotoh, David K. C. Cooper, Chung-Gyu Park, Phillip OʼConnell, Cherie Stabler, Shinichi Matsumoto, Barbara Ludwig, Pratik Choudhary, Boris Kovatchev, Michael R. Rickels, Megan Sykes, Kathryn Wood, Kristy Kraemer, Albert Hwa, Edward Stanley, Camillo Ricordi, Mark Zimmerman, Julia Greenstein, Eduard Montanya, Timo Otonkoski, Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement, Transplantation, 2016, 100, S1

    CrossRef

  6. 6
    D.Q. Zhao, S.W. Li, Q.Q. Sun, Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review, Transplantation Proceedings, 2016, 48, 1, 3

    CrossRef

  7. 7
    Timo Jahnukainen, Anna Bjerre, Marie Larsson, Juuso Tainio, Helle C. Thiesson, Hannu Jalanko, Søren Schwartz Sørensen, Lars Wennberg, The second report of the Nordic Pediatric Renal Transplantation Registry 1997–2012: More infant recipients and improved graft survivals, Pediatric Transplantation, 2016, 20, 3
  8. 8
    R. Brian Stevens, Kirk W. Foster, Clifford D. Miles, James T. Lane, Andre C. Kalil, Diana F. Florescu, John P. Sandoz, Theodore H. Rigley, Kathleen J. Nielsen, Jill Y. Skorupa, Anna M. Kellogg, Tamer Malik, Lucile E. Wrenshall, A Randomized 2×2 Factorial Trial, Part 1, Transplantation, 2015, 99, 1, 197

    CrossRef

  9. 9
    Shuichi TOYODA, Toru EGUCHI, Hiroki TOMA, Yasuhiro OKABE, Ichio HIROTA, Hidehisa KITADA, Acute Diverticulitis with Transverse Colon Perforation 9 Years after Kidney Transplantation, Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2015, 76, 10, 2476

    CrossRef

  10. 10
    Jamal Bamoulid, Oliver Staeck, Fabian Halleck, Michael Dürr, Alexander Paliege, Nils Lachmann, Susanne Brakemeier, Lutz Liefeldt, Klemens Budde, Advances in pharmacotherapy to treat kidney transplant rejection, Expert Opinion on Pharmacotherapy, 2015, 16, 11, 1627

    CrossRef

  11. 11
    Nassim Kamar, Arnaud Del Bello, Julie Belliere, Lionel Rostaing, Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation, Transplant International, 2015, 28, 8
  12. 12
    Sokratis Stoumpos, Alan G. Jardine, Patrick B. Mark, Cardiovascular morbidity and mortality after kidney transplantation, Transplant International, 2015, 28, 1
  13. 13
    Kazuyuki Numakura, Hideaki Kagaya, Ryohei Yamamoto, Naoki Komine, Mitsuru Saito, Tsuruta Hiroshi, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi, Takenori Niioka, Masatomo Miura, Shigeru Satoh, Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation, Disease Markers, 2015, 2015, 1

    CrossRef

  14. 14
    Jan Steffen Jürgensen, Robert Ikenberg, Roger-Axel Greiner, Volker Hösel, Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany, The European Journal of Health Economics, 2015, 16, 4, 377

    CrossRef

  15. 15
    Franc Andreu, Helena Colom, Josep M. Grinyó, Joan Torras, Josep M. Cruzado, Nuria Lloberas, Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients, Therapeutic Drug Monitoring, 2015, 37, 2, 246

    CrossRef

  16. 16
    Louise M Andrews, Natalia Riva, Brenda C de Winter, Dennis A Hesselink, Saskia N de Wildt, Karlien Cransberg, Teun van Gelder, Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients, Expert Opinion on Drug Metabolism & Toxicology, 2015, 11, 6, 921

    CrossRef

  17. 17
    Agnes Debout, Yohann Foucher, Katy Trébern-Launay, Christophe Legendre, Henri Kreis, Georges Mourad, Valérie Garrigue, Emmanuel Morelon, Fanny Buron, Lionel Rostaing, Nassim Kamar, Michèle Kessler, Marc Ladrière, Alexandra Poignas, Amina Blidi, Jean-Paul Soulillou, Magali Giral, Etienne Dantan, Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation, Kidney International, 2015, 87, 2, 343

    CrossRef

  18. 18
    N. Poirier, N. Dilek, C. Mary, S. Ville, F. Coulon, J. Branchereau, X. Tillou, V. Charpy, S. Pengam, V. Nerriere-Daguin, J. Hervouet, D. Minault, S. Le Bas-Bernardet, K. Renaudin, B. Vanhove, G. Blancho, FR104, an Antagonist Anti-CD28 Monovalent Fab' Antibody, Prevents Alloimmunization and Allows Calcineurin Inhibitor Minimization in Nonhuman Primate Renal Allograft, American Journal of Transplantation, 2015, 15, 1
  19. 19
    Franck Saint-Marcoux, Jean-Baptiste Woillard, Caroline Monchaud, Jennifer Friedl, Frédérique Bocquentin, Marie Essig, Pierre Marquet, How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation, Pharmacological Research, 2015, 100, 281

    CrossRef

  20. 20
    B. Schamberger, D. Sollinger, J. Lutz, Immunsuppressive Therapie nach Nierentransplantation, Der Nephrologe, 2015, 10, 1, 9

    CrossRef

  21. 21
    Song Ching Ong, Robert S. Gaston, Medical management of chronic kidney disease in the renal transplant recipient, Current Opinion in Nephrology and Hypertension, 2015, 24, 6, 587

    CrossRef

  22. 22
    Hallvard Holdaas, Luciano Potena, Faouzi Saliba, mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?, Transplantation Reviews, 2015, 29, 2, 93

    CrossRef

  23. 23
    L.J. Lehner, Oliver Staeck, Fabian Halleck, Lutz Liefeldt, Jamal Bamoulid, K. Budde, Need for optimized immunosuppression in elderly kidney transplant recipients, Transplantation Reviews, 2015, 29, 4, 237

    CrossRef

  24. 24
    James A. Hutchinson, Edward K. Geissler, Now or never? The case for cell-based immunosuppression in kidney transplantation, Kidney International, 2015, 87, 6, 1116

    CrossRef

  25. 25
    Alan G. Jardine, Proceedings of the 13th international transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning, Transplantation Research, 2015, 4, S1

    CrossRef

  26. 26
    Daniel Baron, Magali Giral, Sophie Brouard, Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes, Transplant International, 2015, 28, 8
  27. 27
    Aifang Yang, Bin Wang, Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids, American Journal of Therapeutics, 2015, 22, 2, 98

    CrossRef

  28. 28
    Tainá Veras de Sandes-Freitas, Cláudia Rosso Felipe, Érika Fernandes Campos, Maria Gerbasi de Lima, Maria Fernanda Soares, Marcello Fabiano de Franco, Wilson Ferreira Aguiar, Hélio Tedesco-Silva, José Osmar Medina-Pestana, Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus, Transplantation, 2015, 99, 11, 2372

    CrossRef

  29. You have free access to this content29
    Masayoshi Miura, Hiroshi Higashiyama, Yuichiro Fukasawa, Yosuke Itoh, Tohru Tamaki, Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts, Nephrology, 2015, 20,
  30. 30
    Jamal Bamoulid, Oliver Staeck, Fabian Halleck, Dmytri Khadzhynov, Susanne Brakemeier, Michael Dürr, Klemens Budde, The need for minimization strategies: current problems of immunosuppression, Transplant International, 2015, 28, 8
  31. 31
    Paolo Malvezzi, Lionel Rostaing, The safety of calcineurin inhibitors for kidney-transplant patients, Expert Opinion on Drug Safety, 2015, 14, 10, 1531

    CrossRef

  32. 32
    Joke I. Roodnat, Luuk B. Hilbrands, Ronald J. Hené, Ruud G.L. de Sévaux, Peter J.H. Smak Gregoor, Judith A. Kal-van Gestel, Cynthia Konijn, Arjan van Zuilen, Teun van Gelder, Andries J. Hoitsma, Willem Weimar, 15-Year Follow-up of a Multicenter, Randomized, Calcineurin Inhibitor Withdrawal Study in Kidney Transplantation, Transplantation, 2014, 98, 1, 47

    CrossRef

  33. 33
    Jeffrey S. Zaltzman, Vesta Lai, Miklos Z. Schulz, Kyung-Hee Moon, David Z. Cherney, A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers, Transplant International, 2014, 27, 12
  34. 34
    Yaerim Kim, Sungbae Park, Hyoungtae Kim, Seungyeup Han, Actual 10-year Outcomes of Tacrolimus/MMF Compared with Cyclosporin/MMF in Kidney Transplantation, The Journal of the Korean Society for Transplantation, 2014, 28, 2, 69

    CrossRef

  35. 35
    M. Zachariah, N.D. Nader, J. Brar, N. Singh, R. Venuto, S. Patel, M. Said, M.R. Laftavi, O. Pankewycz, Alemtuzumab and Minimization Immunotherapy in Kidney Transplantation: Long-Term Results of Comparison With Rabbit Anti-Thymocyte Globulin and Standard Triple Maintenance Therapy, Transplantation Proceedings, 2014, 46, 1, 94

    CrossRef

  36. 36
    S. Nakazawa, H. Kishikawa, M. Kawamura, N. Ueda, T. Hirai, K. Nishimura, Conversion to Mycophenolate Mofetil From Azathioprine Shows Significant Positive Effect on Graft Function in Long-Term Past–Kidney Transplantation Stable-State Patients, Transplantation Proceedings, 2014, 46, 2, 411

    CrossRef

  37. 37
    Johanna Savikko, Anna-Maija Teppo, Eero Taskinen, Eva von Willebrand, Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: Evidence for improved kidney graft outcome, Transplant Immunology, 2014, 31, 3, 145

    CrossRef

  38. 38
    Torben Schweer, Wilfried Gwinner, Irina Scheffner, Anke Schwarz, Hermann Haller, Cornelia Blume, High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation, Clinical Transplantation, 2014, 28, 4
  39. 39
    Catherine Cornu, Christophe Dufays, Ségolène Gaillard, François Gueyffier, Michel Redonnet, Laurent Sebbag, Ana Roussoulières, Christian A. Gleissner, Jan Groetzner, Hans B. Lehmkuhl, Luciano Potena, Lars Gullestad, Marcelo Cantarovich, Pascale Boissonnat, Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis, British Journal of Clinical Pharmacology, 2014, 78, 1
  40. 40
    R. Joost, F. Dorje, J. Schwitulla, K.-U. Eckardt, C. Hugo, Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental study, Nephrology Dialysis Transplantation, 2014, 29, 8, 1597

    CrossRef

  41. 41
    Hélio Tedesco Silva, Harold C. Yang, Herwig-Ulf Meier-Kriesche, Richard Croy, John Holman, William E. Fitzsimmons, M. Roy First, Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients, Transplantation, 2014, 97, 6, 636

    CrossRef

  42. 42
    J. Beimler, C. Morath, M. Zeier, Moderne Immunsuppression nach Organtransplantation, Der Internist, 2014, 55, 2, 212

    CrossRef

  43. 43
    Lars Pape, Thurid Ahlenstiel, mTOR inhibitors in pediatric kidney transplantation, Pediatric Nephrology, 2014, 29, 7, 1119

    CrossRef

  44. 44
    N. Murakami, L. V. Riella, T. Funakoshi, Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis, American Journal of Transplantation, 2014, 14, 10
  45. 45
    Fuad S. Shihab, Ali Olyaei, Anne Wiland, Kevin McCague, Douglas J. Norman, Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study, Clinical Transplantation, 2014, 28, 7
  46. 46
    Nicholas Larkins, Douglas G. Matsell, Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomes, Pediatric Transplantation, 2014, 18, 8
  47. 47
    H. Xu, S. D. Perez, J. Cheeseman, A. K. Mehta, A. D. Kirk, The Allo- and Viral-Specific Immunosuppressive Effect of Belatacept, but Not Tacrolimus, Attenuates With Progressive T Cell Maturation, American Journal of Transplantation, 2014, 14, 2
  48. 48
    Yash Pal Agrawal, Maria Cid, Sten Westgard, Thomas S. Parker, Ryan Jaikaran, Daniel M. Levine, Transplant Patient Classification and Tacrolimus Assays, Therapeutic Drug Monitoring, 2014, 36, 6, 706

    CrossRef

  49. 49
    M. Opgenoorth, C. Hugo, Tumoren nach Nierentransplantation, Forum, 2014, 29, 2, 125

    CrossRef

  50. 50
    Robert P. Carroll, Jeremy R. Chapman, Can the Risk of Skin Cancer After Transplantation Be Reduced by mTOR Inhibitors?, American Journal of Kidney Diseases, 2013, 61, 5, 698

    CrossRef

  51. 51
    Philippe Gatault, Yvon Lebranchu, Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?, Transplantation Research, 2013, 2, Suppl 1, S3

    CrossRef

  52. 52
    Madeleine Nilsson, Anna Forsberg, Annette Lennerling, Lars-Olof Persson, Coping in relation to perceived threat of the risk of graft rejection and Health-Related Quality of Life of organ transplant recipients, Scandinavian Journal of Caring Sciences, 2013, 27, 4
  53. 53
    Sebastian M Schaefer, Caner Süsal, Claudia Sommerer, Martin Zeier, Christian Morath, Current pharmacotherapeutical options for the prevention of kidney transplant rejection, Expert Opinion on Pharmacotherapy, 2013, 14, 8, 1029

    CrossRef

  54. 54
    Siah Kim, Angela C. Webster, Jonathan C. Craig, Current trends in immunosuppression following organ transplantation in children, Current Opinion in Organ Transplantation, 2013, 18, 5, 537

    CrossRef

  55. 55
    Anthony Langone, Cataldo Doria, Stuart Greenstein, Mohanram Narayanan, Kimi Ueda, Bashir Sankari, Oleh Pankewycz, Fuad Shihab, Laurence Chan, Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry, Clinical Transplantation, 2013, 27, 1
  56. 56
    Yanwen Peng, Ming Ke, Lu Xu, Longshan Liu, Xiaoyong Chen, Wenjie Xia, Xiaobo Li, Zhen Chen, Junjie Ma, Dehuai Liao, Guanghui Li, Jiali Fang, Guanghui Pan, Andy Peng Xiang, Donor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation, Transplantation Journal, 2013, 95, 1, 161

    CrossRef

  57. 57
    R. Ganschow, L. Pape, E. Sturm, J. Bauer, M. Melter, P. Gerner, B. Höcker, T. Ahlenstiel, M. Kemper, F. Brinkert, M. M. Sachse, B. Tönshoff, Growing experience with mTOR inhibitors in pediatric solid organ transplantation, Pediatric Transplantation, 2013, 17, 7
  58. 58
    T. Feldkamp, A. Linkermann, Immunsuppressive Therapie nach Nierentransplantation, Der Nephrologe, 2013, 8, 3, 217

    CrossRef

  59. 59
    T. Isakova, H. Xie, S. Messinger, F. Cortazar, J. J. Scialla, G. Guerra, G. Contreras, D. Roth, G. W. Burke, M. Z. Molnar, I. Mucsi, M. Wolf, Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation, American Journal of Transplantation, 2013, 13, 1
  60. 60
    Rubin Zhang, Modern Immunosuppressive Therapy in Kidney Transplantation, Open Journal of Organ Transplant Surgery, 2013, 03, 02, 22

    CrossRef

  61. 61
    F. Halleck, F. Friedersdorff, T.F. Fuller, M. Matz, L. Huber, M. Dürr, M. Schütz, K. Budde, New Perspectives of Immunosuppression, Transplantation Proceedings, 2013, 45, 3, 1224

    CrossRef

  62. 62
    Graeme R Russ, Optimising the use of mTOR inhibitors in renal transplantation, Transplantation Research, 2013, 2, Suppl 1, S4

    CrossRef

  63. 63
    Celline Almeida, Micheline Silveira, Vânia de Araújo, Livia de Lemos, Juliana de Oliveira Costa, Carlos Reis, Francisco de Assis Acurcio, Maria das Gracas Braga Ceccato, Safety of Immunosuppressive Drugs Used as Maintenance Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis, Pharmaceuticals, 2013, 6, 10, 1170

    CrossRef

  64. 64
    Matthias Schaier, Nicole Seissler, Luis Eduardo Becker, Sebastian Markus Schaefer, Edgar Schmitt, Stefan Meuer, Friederike Hug, Claudia Sommerer, Rüdiger Waldherr, Martin Zeier, Andrea Steinborn, The extent of HLA-DR expression on HLA-DR+ Tregs allows the identification of patients with clinically relevant borderline rejection, Transplant International, 2013, 26, 3
  65. 65
    M. Guba, J. Andrassy, M. Angele, C. Bruns, Tumor und Transplantation, Der Chirurg, 2013, 84, 8, 690

    CrossRef

  66. 66
    M. Opgenoorth, C. Hugo, Tumoren nach Nierentransplantation, best practice onkologie, 2013, 8, 1, 38

    CrossRef

  67. 67
    M. Opgenoorth, C. Hugo, Tumoren nach Nierentransplantation, Der Onkologe, 2013, 19, 3, 237

    CrossRef

  68. 68
    Fabian Halleck, Michael Duerr, Johannes Waiser, Lu Huber, Mareen Matz, Susanne Brakemeier, Lutz Liefeldt, Hans-Hellmut Neumayer, Klemens Budde, An evaluation of sirolimus in renal transplantation, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 10, 1337

    CrossRef

  69. 69
    Flavio Vincenti, Are calcineurin inhibitors-free regimens ready for prime time?, Kidney International, 2012, 82, 10, 1054

    CrossRef

  70. 70
    J. Uchida, N. Kuwabara, Y. Machida, T. Iwai, T. Naganuma, N. Kumada, T. Nakatani, Conversion of Stable Kidney Transplant Recipients From a Twice-Daily Prograf to a Once-Daily Tacrolimus Formulation: A Short-Term Study on its Effects on Glucose Metabolism, Transplantation Proceedings, 2012, 44, 1, 128

    CrossRef

  71. 71
    A. Hoerning, S. Köhler, C. Jun, J. Lu, J. Fu, B. Tebbe, S. Dolff, T. Feldkamp, A. Kribben, P. F. Hoyer, O. Witzke, Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients, Clinical & Experimental Immunology, 2012, 168, 2
  72. 72
    L. V. Riella, S. Gabardi, A. Chandraker, Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation, American Journal of Transplantation, 2012, 12, 8
  73. 73
    Pamala A. Jacobson, David Schladt, Ajay Israni, William S. Oetting, Yi Cheng Lin, Robert Leduc, Weihau Guan, Vishal Lamba, Arthur J. Matas, Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity, Transplantation, 2012, 1

    CrossRef

  74. 74
    Walter D. Park, Timothy S. Larson, Matthew D. Griffin, Mark D. Stegall, Identification and Characterization of Kidney Transplants With Good Glomerular Filtration Rate at 1 Year But Subsequent Progressive Loss of Renal Function, Transplantation Journal, 2012, 94, 9, 931

    CrossRef

  75. 75
    Pascale Boissonnat, Ségolène Gaillard, Catherine Mercier, Michel Redonnet, Bernard Lelong, Marie-Françoise Mattei, Annick Mouly-Bandini, Sabine Pattier, Agnès Sirinelli, Eric Epailly, Shaida Varnous, Marc-Alain Billes, Laurent Sebbag, René Ecochard, Catherine Cornu, François Gueyffier, Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial, Trials, 2012, 13, 1, 231

    CrossRef

  76. 76
    Cyril Garrouste, Nassim Kamar, Céline Guilbeau-Frugier, Joëlle Guitard, Laure Esposito, Laurence Lavayssière, Marie-Béatrice Nogier, Olivier Cointault, David Ribes, Lionel Rostaing, Long-term Results of Conversion From Calcineurin Inhibitors to Sirolimus in 150 Maintenance Kidney Transplant Patients, Experimental and Clinical Transplantation, 2012, 10, 2, 110

    CrossRef

  77. 77
    Susumu Shibasaki, Kenichiro Yamashita, Ryoichi Goto, Tetsu Oura, Kenji Wakayama, Gentaro Hirokata, Tomohiro Shibata, Rumi Igarashi, Sanae Haga, Michitaka Ozaki, Satoru Todo, NK026680 inhibits T-cell function in an IL-2-dependent manner and prolongs cardiac allograft survival in rats, Transplant Immunology, 2012, 26, 1, 42

    CrossRef

  78. 78
    Paul J. Taylor, Michael E. Franklin, Chun-Hui Tai, Peter I. Pillans, Therapeutic drug monitoring of tacrolimus by liquid chromatography–tandem mass spectrometry: Is it truly a routine test?, Journal of Chromatography B, 2012, 883-884, 108

    CrossRef

  79. You have free access to this content79
    F. Vincenti, C. P. Larsen, J. Alberu, B. Bresnahan, V. D. Garcia, J. Kothari, P. Lang, E. Mancilla Urrea, P. Massari, G. Mondragon-Ramirez, R. Reyes-Acevedo, K. Rice, L. Rostaing, S. Steinberg, J. Xing, M. Agarwal, M. B. Harler, B. Charpentier, Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients, American Journal of Transplantation, 2012, 12, 1
  80. 80
    M. Opgenoorth, C. Hugo, Tumoren nach Nierentransplantation, Der Nephrologe, 2012, 7, 5, 435

    CrossRef

  81. 81
    Junichi Hoshino, Hugo Kaneku, Matthew J. Everly, Sander Greenland, Paul I. Terasaki, Using Donor-Specific Antibodies to Monitor the Need for Immunosuppression, Transplantation Journal, 2012, 93, 11, 1173

    CrossRef

  82. 82
    Jane C. Tan, Stéphan Busque, John D. Scandling, Brenner and Rector's The Kidney, 2012,

    CrossRef

  83. 83
    Michael Jin Casey, Herwig-Ulf Meier-Kriesche, Calcineurin inhibitors in kidney transplantation, Current Opinion in Nephrology and Hypertension, 2011, 20, 6, 610

    CrossRef

  84. 84
    O. Pankewycz, N. Leca, R. Kohli, E. Weber-Shrikant, M. Said, M. Alnimri, L. Feng, S. Patel, M.R. Laftavi, Conversion to Low-Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplantation: A Prospective, Protocol Biopsy-Guided Study, Transplantation Proceedings, 2011, 43, 2, 519

    CrossRef

  85. 85
    Y. Lebranchu, A. Thierry, E. Thervet, M. Büchler, I. Etienne, P. F. Westeel, B. Hurault de Ligny, B. Moulin, J. P. Rérolle, T. Frouget, S. Girardot-Seguin, O. Toupance, Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept Study, American Journal of Transplantation, 2011, 11, 8
  86. 86
    Roberto Marcén, Immunosuppression and renal transplant rejection: review of current and emerging therapies, Clinical Investigation, 2011, 1, 6, 859

    CrossRef

  87. 87
    Ben Sprangers, Dirk R. Kuypers, Yves Vanrenterghem, Immunosuppression: Does One Regimen Fit All?, Transplantation, 2011, 92, 3, 251

    CrossRef

  88. 88
    Rolf Weimer, Sabine Deisz, Hartmut Dietrich, Fabrice Renner, Rolf-Hasso Bödeker, Volker Daniel, Shirin Kamali-Ernst, Wolfgang Ernst, Winfried Padberg, Gerhard Opelz, Impact of maintenance immunosuppressive regimens – balance between graft protective suppression of immune functions and a near physiological immune response, Transplant International, 2011, 24, 6
  89. 89
    Farida Abadja, Stéphanie Atemkeng, Eric Alamartine, François Berthoux, Christophe Mariat, Impact of Mycophenolic Acid and Tacrolimus on Th17-Related Immune Response, Transplantation, 2011, 92, 4, 396

    CrossRef

  90. 90
    A. Kolonko, J. Chudek, A. Wie̢cek, Improved Kidney Graft Function After Conversion From Twice Daily Tacrolimus to a Once Daily Prolonged-Release Formulation, Transplantation Proceedings, 2011, 43, 8, 2950

    CrossRef

  91. 91
    Alicia N. McMurchy, Andrew Bushell, Megan K. Levings, Kathryn J. Wood, Moving to tolerance: Clinical application of T regulatory cells, Seminars in Immunology, 2011, 23, 4, 304

    CrossRef

  92. 92
    K. Midtvedt, T. Jenssen, A. Hartmann, N. T. Vethe, S. Bergan, K. Havnes, A. Asberg, No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus, Nephrology Dialysis Transplantation, 2011, 26, 11, 3767

    CrossRef

  93. 93
    Christos Chatzikyrkou, Jan Menne, Wilfried Gwinner, Bernhard M. Schmidt, Frank Lehner, Cornelia Blume, Anke Schwarz, Hermann Haller, Mario Schiffer, Pathogenesis and management of hypertension after kidney transplantation, Journal of Hypertension, 2011, 29, 12, 2283

    CrossRef

  94. 94
    Lars Pape, Frank Lehner, Cornelia Blume, Thurid Ahlenstiel, Pediatric Kidney Transplantation Followed by De Novo Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data, Transplantation, 2011, 92, 6, 658

    CrossRef

  95. 95
    Gaetano Ciancio, Jeffrey J. Gaynor, Junichiro Sageshima, Giselle Guerra, Alberto Zarak, David Roth, Randolph Brown, Warren Kupin, Linda Chen, Lois Hanson, Lissett Tueros, Phillip Ruiz, Alan S. Livingstone, George W. Burke, Randomized Trial of Dual Antibody Induction Therapy With Steroid Avoidance in Renal Transplantation, Transplantation, 2011, 92, 12, 1348

    CrossRef

  96. 96
    Gaetano Ciancio, Jeffrey J. Gaynor, Alberto Zarak, Junichiro Sageshima, Giselle Guerra, David Roth, Randolph Brown, Warren Kupin, Linda Chen, Lissett Tueros, Lois Hanson, Phillip Ruiz, George W. Burke, Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplantation With Tacrolimus and Steroid Avoidance: Four-Year Analysis, Transplantation, 2011, 91, 11, 1198

    CrossRef

  97. 97
    K. Boudjema, C. Camus, F. Saliba, Y. Calmus, E. Salamé, G. Pageaux, C. Ducerf, C. Duvoux, C. Mouchel, A. Renault, P. Compagnon, R. Lorho, E. Bellissant, Reduced-Dose Tacrolimus with Mycophenolate Mofetil vs. Standard-Dose Tacrolimus in Liver Transplantation: A Randomized Study, American Journal of Transplantation, 2011, 11, 5
  98. 98
    Huimin Fan, Peng Cao, David S. Game, Francesco Dazzi, Zhongmin Liu, Shuiping Jiang, Regulatory T cell therapy for the induction of clinical organ transplantation tolerance, Seminars in Immunology, 2011, 23, 6, 453

    CrossRef

  99. 99
    R. Baker, A. Jardine, Peter Andrews, Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant Recipient, Nephron Clinical Practice, 2011, 118, s1, c311

    CrossRef

  100. 100
    I. Helal, L. Chan, Steroid and Calcineurin Inhibitor—Sparing Protocols in Kidney Transplantation, Transplantation Proceedings, 2011, 43, 2, 472

    CrossRef

  101. 101
    Johan W. de Fijter, Tacrolimus Dosing in Mycophenolate-Treated Patients—Can We Get Away With Less?, Transplantation, 2011, 92, 1, 10

    CrossRef

  102. 102
    S. Busque, M. Cantarovich, S. Mulgaonkar, R. Gaston, A. O. Gaber, P. R. Mayo, S. Ling, R. B. Huizinga, H-U. Meier-Kriesche, The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation, American Journal of Transplantation, 2011, 11, 12
  103. 103
    D. Spoerl, Andreas J. Bircher, A worldwide yearly survey of new data in adverse drug reactions, 2011,

    CrossRef

  104. 104
    Jeffrey S. Zaltzman, A Comparison of Short-Term Exposure of Once-Daily Extended Release Tacrolimus and Twice-Daily Cyclosporine on Renal Function in Healthy Volunteers, Transplantation, 2010, 90, 11, 1185

    CrossRef

  105. 105
    Christian P. Larsen, Josep Grinyó, José Medina-Pestana, Yves Vanrenterghem, Flavio Vincenti, Barbara Breshahan, Josep M. Campistol, Sander Florman, Maria del Carmen Rial, Nassim Kamar, Alan Block, Gregory Di Russo, Chen-Sheng Lin, Pushkal Garg, Bernard Charpentier, Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies, Transplantation, 2010, 90, 12, 1528

    CrossRef

  106. 106
    Andy Lunn, Jane Ravenscroft, Alan R. Watson, Cutaneous warts in children before and after renal transplantation, Pediatric Nephrology, 2010, 25, 5, 941

    CrossRef

  107. 107
    R. A. H. Haynes, E. Ware, C. Premanandan, B. Zimmerman, L. Yu, A. J. Phipps, M. D. Lairmore, Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model, Blood, 2010, 115, 4, 815

    CrossRef

  108. 108
    L. Pape, G. Offner, M. Kreuzer, K. Froede, J. Drube, N. Kanzelmeyer, J. H. H. Ehrich, T. Ahlenstiel, De novo Therapy with Everolimus, Low-Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation, American Journal of Transplantation, 2010, 10, 10
  109. 109
    C. Morath, M. Zeier, C. Sommerer, Immunsuppression nach Nierentransplantation, Der Nephrologe, 2010, 5, 2, 108

    CrossRef

  110. 110
    Margaret Bia, Deborah B. Adey, Roy D. Bloom, Laurence Chan, Sanjay Kulkarni, Steven Tomlanovich, KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, American Journal of Kidney Diseases, 2010, 56, 2, 189

    CrossRef

  111. 111
    Josep M Grinyó, Oriol Bestard, Joan Torras, Josep M Cruzado, Optimal immunosuppression to prevent chronic allograft dysfunction, Kidney International, 2010, 78, S66

    CrossRef

  112. 112
    Arjang Djamali, Carolynn E Pietrangeli, Robert D Gordon, Christophe Legendre, Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile, Kidney International, 2010, 78, S15

    CrossRef

  113. 113
    Dirk R J Kuypers, Maarten Naesens, Hylke de Jonge, Evelyne Lerut, Kristin Verbeke, Yves Vanrenterghem, Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients, Therapeutic Drug Monitoring, 2010, 32, 4, 394

    CrossRef

  114. 114
    Jin Min Kong, Malignancy in Renal Transplant Recipients, The Journal of the Korean Society for Transplantation, 2009, 23, 2, 130

    CrossRef

  115. 115
    Josep M. Grinyó, Josep M. Cruzado, Mycophenolate Mofetil and Calcineurin-Inhibitor Reduction: Recent Progress, American Journal of Transplantation, 2009, 9, 11
  116. 116
    Philip Masson, Lorna Henderson, Jeremy R Chapman, Jonathan C Craig, Angela C Webster, Belatacept for kidney transplant recipients, The Cochrane Library,
  117. 117
    Oriol Bestard, Josep M. Cruzado, Josep M. Grinyó, General Malignancy after Organ Transplantation,
  118. 118
    Steven Gabardi, Anil Chandraker, Immunosuppressive Pharmacotherapy,
  119. 119
    Naim Issa, Scott A. Reule, Aleksandra Kukla, Metabolic and Endocrine Management of the Organ Transplant Recipient,